The UAB Comprehensive Cancer Center Senior Leadership is comprised of seven individuals supported by the CCSG: Director - Edward E. Partridge, IVI.D. Deputy Director- Boris C. Pasche, M.D., Ph.D. Associate Director for Basic Research - Etty (Tika) Benveniste, Ph.D. Associate Director for Translational Research - Mary-Ann Bjornsti, Ph.D. Associate Director for Clinical Research - Albert F. LoBuglio, M.D. Associate Director for Prevention and Control - Wendy Demark-Wahnefried, Ph.D. Associate Director for Administration - Michael J. Bertram, Ph.D. There have been major changes in Senior Leadership since the last competitive renewal. Following a national search for a new Director, Dr. Edward E. Partridge was named Director in July of 2007. Dr. Partridge has a longstanding history in the UAB Comprehensive Cancer Center (UAB CCC) and has played various leadership roles over the past two decades. His primary areas of expertise include clinical and cancer control research. Other new Senior Leaders include Dr. Boris C. Pasche as Deputy Director, replacing Dr. Kirby Bland, now Senior Advisor to the Director;Dr. Etty Benveniste as Associate Director for Basic Research, replacing Dr. Robert Diasio, now Director of the Mayo Comprehensive Cancer Center;Dr. Albert LoBuglio as Associate Director for Clinical Research, following Dr. Sam Beenken's departure;Dr. Mary-Ann Bjornsti to the newly created position of Associate Director for Translational Research;Dr. Wendy Demark-Wahnefried as Associate Director for Prevention and Control, replacing Dr. Partridge;and Dr. Michael Bertram as Associate Director for Administration.
Because of the investment of the National Cancer Institute in a Comprehensive Cancer Center, the center needs leadership that understands stewardship of public trust. The UAB CCC leadership's mission is to assure that the center fulfills the NCI goals of reducing morbidity and mortality from cancer;discovering the nature of cancer;understanding cancer biology;developing effective prevention, diagnosis, and therapy.; delivering medical advances to patients and their families;educating healthcare professionals and the public; and reaching out to underserved populations.
|Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27|
|Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:|
|Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14|
|Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913|
|Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210|
|Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230|
|Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340|
|Banerjee, N Sanjib; Wang, Hsu-Kun; Beadle, James R et al. (2018) Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. Antiviral Res 150:164-173|
|Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34|
|Kleinpeter, Alex B; Jureka, Alexander S; Falahat, Sally M et al. (2018) Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds. J Biol Chem 293:14659-14668|
Showing the most recent 10 out of 747 publications